CXCR: C-X-C motif receptor
12 Preliminary data from the T-REX trial, which combined a GLP-1 agonist with a structured resistance-training program, landed in the same range: the training arm cut fat-free-mass loss roughly in half compared with medication alone
Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
Hydrates & Nourishes Skin: Infused with moisturizing agents to keep your skin soft, smooth, and hydrated, preventing dryness and flakiness
To learn more, see the companys terms and conditions and privacy policy